These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 7684167)

  • 21. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cytokine therapy for metastatic renal cell carcinoma].
    Eto M; Naito S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex.
    Daniels GA; Galanis E
    Curr Opin Mol Ther; 2001 Feb; 3(1):70-6. PubMed ID: 11249734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C
    Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
    Négrier S; Philip T
    Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
    Brinkmann OA; Bruns F; Prott FJ; Hertle L
    Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Systemic treatment of renal-cell carcinoma--present status].
    Steiner T; Schubert J
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1080-4. PubMed ID: 11602916
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical applications of IL-2.
    Sznol M; Parkinson DR
    Oncology (Williston Park); 1994 Jun; 8(6):61-7; discussion 67, 71, 74-5. PubMed ID: 7521197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer.
    Wirth M
    Urol Int; 1991; 47(4):219-30. PubMed ID: 1723554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic options in renal cell carcinoma.
    Buzaid AC; Todd MB
    Semin Oncol; 1989 Feb; 16(1 Suppl 1):12-9. PubMed ID: 2465574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Renal cancer :therapeutical dilemma].
    Miron L; Ciornea L
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(3):475-80. PubMed ID: 12092176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
    Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for renal cell carcinoma.
    Belldegrun A; Figlin R; Danella J; deKernion J
    Semin Urol; 1992 Feb; 10(1):23-7. PubMed ID: 1565900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The immunotherapy of advanced renal cell carcinoma].
    Bergmann L; Weidmann E; Mitrou PS
    Dtsch Med Wochenschr; 1991 Mar; 116(10):384-90. PubMed ID: 1705879
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.